Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
IMV Inc. downgraded to Neutral from Buy at B. Riley FBR » 08:29
04/01/20
04/01
08:29
04/01/20
08:29
IMV

IMV Inc.

$1.67 /

-0.02 (-1.18%)

B. Riley FBR analyst…

B. Riley FBR analyst Mayank Mamtani downgraded IMV Inc. to Neutral from Buy with a price target of $3, down from $7. The analyst sees increased uncertainty to DPX-Survivac's registration pathway in a "highly competitive" late-stage recurrent/refractory ovarian cancer landscape. Further, IMV's recent announcement of pursuing a COVID-19 vaccine puts additional pressure on a "relatively weak" balance sheet, Mamtani tells investors in a research note.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Monday
Hot Stocks
IMV Inc. provides up date on DPX-COVID-19 vaccine » 07:30
03/30/20
03/30
07:30
03/30/20
07:30
IMV

IMV Inc.

$1.62 /

-0.08 (-4.71%)

IMV Inc. provided…

IMV Inc. provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel coronavirus, and on the company's business and clinical operations amid the COVID-19 pandemic. "As the COVID-19 pandemic continues to spread, we have taken all necessary measures to prioritize the health and safety of our employees, patients, investigators and each of their families. In parallel, we remain committed to serving the unmet needs of patients, both through our efforts to potentially develop a prophylactic vaccine to curb this novel coronavirus and across our ongoing clinical studies with DPX-Survivac in advanced-stage cancer patients," said Frederic Ors, CEO of IMV. "We are committed to progressing the development of our DPX-COVID-19 vaccine candidate working expeditiously with our partners to advance human clinical studies as fast as possible."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
Downgrade
IMV Inc. downgraded to Market Perform from Outperform at Raymond James » 15:02
03/18/20
03/18
15:02
03/18/20
15:02
IMV

IMV Inc.

$2.16 /

+0.14 (+6.93%)

Raymond James analyst…

Raymond James analyst David Novak downgraded IMV Inc. to Market Perform from Outperform with a price target of $3.00, down from $4.50.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
IMV Inc. plans to advance clinical development of COVID-19 vaccine candidate » 07:16
03/18/20
03/18
07:16
03/18/20
07:16
IMV

IMV Inc.

$2.02 /

+0.2 (+10.99%)

IMV Inc. announced that…

IMV Inc. announced that it is advancing the clinical development of a DPX-based vaccine candidate against COVID-19. Vaccines against infectious disease have been a core part of IMV's heritage across its DPX platform technology. The goal of this development program will be to establish the clinical safety and immunogenicity of a vaccine candidate based on the Company's DPX delivery technology and incorporating peptides targeting novel epitopes from the coronavirus strain. The Company believes that this peptide-based approach, combined with the portability of the DPX platform, offers the potential for accelerated development and rapid, large-scale production of a vaccine. The company intends to develop its vaccine candidate DPX-COVID-19 in collaboration with lead investigators for the phase 1 clinical study: Joanne Langley, M.D. and Scott Halperin, M.D., of the Canadian Center for Vaccinology, or CCfV, at Dalhousie University, the Izaak Walton Killam Health Center and the Nova Scotia Health Authority and the Canadian Immunization Research Network, or CIRN; along with Dr. Gary Kobinger, Ph.D., Director of the Research Centre on Infectious Diseases at the University Laval in Quebec City and Global Urgent and Advanced Research and Development in Canada. The investigators will assist with preclinical and clinical evaluation and with further development strategy in collaboration with the Canadian government and others.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Recommendations
IMV Inc. selloff this weekend is overdone, says B. Riley FBR » 09:09
02/28/20
02/28
09:09
02/28/20
09:09
IMV

IMV Inc.

$2.37 /

-0.32 (-11.90%)

B. Riley FBR analyst…

B. Riley FBR analyst Mayank Mamtani lowered the firm's price target on IMV Inc. to $7 from $11 and reiterates a Buy rating on the shares. The analyst believes the 40% selloff this week in the shares is overdone ahead of two key catalysts in Q2: the Phase II SPiReL DLBCL full readout and Phase II DPX-Survivac/Keytruda combination basket trial interim analysis in solid tumors. The reduced price target reflects IMV's longer therapy duration needed in its pivotal program and higher market volatility particularly for risk-on assets.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
IMV Inc.to hold a KOL webcast » 08:35
02/27/20
02/27
08:35
02/27/20
08:35
IMV

IMV Inc.

$2.69 /

-0.15 (-5.28%)

Key Opinion Leader…

Key Opinion Leader Symposium on Role of Survivin in Cancer Biology and Potential of DPX-Survivac will be held on February 27 at 8:30 am. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
IMV's DeCidE1 results 'quite encouraging,' says H.C. Wainwright » 11:46
02/25/20
02/25
11:46
02/25/20
11:46
IMV

IMV Inc.

$3.36 /

-1.41 (-29.56%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $11.50 price target on IMV Inc. after the company announced breakthrough data from its DeCidE1 study that "delivers the goods." Pantginis said that DPX-Survivac appears to be breaking new ground as project, as it was among the first in vivo T cell therapies to show clinical activity in hard-to-treat solid tumors. The analyst said that the results are "quite encouraging" to her, and point to a potential accelerated path forward following planned talks with the FDA.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
IMV Inc. downgraded to Equal Weight at Wells Fargo » 11:27
02/25/20
02/25
11:27
02/25/20
11:27
IMV

IMV Inc.

$3.66 /

-1.11 (-23.27%)

, MRK

Merck

$80.70 /

-0.63 (-0.77%)

As previously reported,…

As previously reported, Wells Fargo analyst Jim Birchenough downgraded IMV Inc. (IMV) to Equal Weight from Overweight with a price target of $3.50, down from $6, as he reduces the likelihood of success of DPX-Survivac following review of top-line DeCidE1 data for DPX-Survivac in advanced ovarian cancer. The analyst believes that reported response rate of 22% is difficult to separate from background response rate seen historically with accompanying low-dose cyclophosphamide and believes a clear path to approval is unclear. Birchenough would await longer term follow up data and translational data from DeCidE1 that might identify response factors as well as basket study results with Merck's (MRK) Keytruda to better assess DPX-Survivac opportunity.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
IMV Inc. downgraded to Equal Weight from Overweight at Wells Fargo » 11:21
02/25/20
02/25
11:21
02/25/20
11:21
IMV

IMV Inc.

$3.66 /

-1.11 (-23.27%)

Wells Fargo analyst Jim…

Wells Fargo analyst Jim Birchenough downgraded IMV Inc. to Equal Weight from Overweight with a price target of $3.50, down from $6.00.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
IMV Inc. to host conference call » 07:25
02/25/20
02/25
07:25
02/25/20
07:25
IMV

IMV Inc.

$4.77 /

+ (+0.00%)

Management holds a…

Management holds a conference call to discuss updated results Of Phase 2 DeCidE1 Study on February 25 at 8 am. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.